Wealthfront Advisers’s ResMed RMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.36M | Sell |
10,514
-1,682
| -14% | -$419K | 0.01% | 575 |
|
|
2025
Q4 | $2.94M | Sell |
12,196
-1,643
| -12% | -$420K | 0.01% | 522 |
|
|
2025
Q3 | $3.79M | Buy |
13,839
+209
| +2% | +$57.1K | 0.01% | 450 |
|
|
2025
Q2 | $3.52M | Buy |
13,630
+4,250
| +45% | +$1.01M | 0.01% | 445 |
|
|
2025
Q1 | $2.1M | Buy |
9,380
+1,338
| +17% | +$312K | 0.01% | 525 |
|
|
2024
Q4 | $1.84M | Buy |
8,042
+224
| +3% | +$53.9K | 0.01% | 541 |
|
|
2024
Q3 | $1.91M | Buy |
7,818
+734
| +10% | +$164K | 0.01% | 510 |
|
|
2024
Q2 | $1.36M | Sell |
7,084
-186
| -3% | -$37.7K | ﹤0.01% | 567 |
|
|
2024
Q1 | $1.44M | Buy |
7,270
+15
| +0.2% | +$2.75K | 0.01% | 546 |
|
|
2023
Q4 | $1.25M | Buy |
7,255
+2,583
| +55% | +$397K | ﹤0.01% | 555 |
|
|
2023
Q3 | $691K | Sell |
4,672
-4,376
| -48% | -$791K | ﹤0.01% | 625 |
|
|
2023
Q2 | $1.98M | Sell |
9,048
-794
| -8% | -$177K | 0.01% | 416 |
|
|
2023
Q1 | $2.16M | Buy |
9,842
+257
| +3% | +$55.8K | 0.01% | 395 |
|
|
2022
Q4 | $1.99M | Sell |
9,585
-1,314
| -12% | -$289K | 0.01% | 405 |
|
|
2022
Q3 | $2.38M | Buy |
10,899
+515
| +5% | +$117K | 0.01% | 328 |
|
|
2022
Q2 | $2.18M | Buy |
10,384
+2,217
| +27% | +$472K | 0.01% | 358 |
|
|
2022
Q1 | $1.98M | Sell |
8,167
-271
| -3% | -$65.5K | 0.01% | 399 |
|
|
2021
Q4 | $2.2M | Sell |
8,438
-402
| -5% | -$104K | 0.01% | 361 |
|
|
2021
Q3 | $2.33M | Buy |
8,840
+862
| +11% | +$236K | 0.01% | 316 |
|
|
2021
Q2 | $1.97M | Buy |
7,978
+21
| +0.3% | +$4.42K | 0.01% | 310 |
|
|
2021
Q1 | $1.54M | Buy |
7,957
+258
| +3% | +$51.7K | 0.01% | 317 |
|
|
2020
Q4 | $1.64M | Sell |
7,699
-489
| -6% | -$97.5K | 0.01% | 271 |
|
|
2020
Q3 | $1.4M | Buy |
8,188
+462
| +6% | +$85.3K | 0.01% | 251 |
|
|
2020
Q2 | $1.48M | Sell |
7,726
-1,299
| -14% | -$213K | 0.01% | 231 |
|
|
2020
Q1 | $1.33M | Buy |
9,025
+4,864
| +117% | +$775K | 0.01% | 207 |
|
|
2019
Q4 | $645K | Sell |
4,161
-16
| -0.4% | -$2.31K | ﹤0.01% | 376 |
|
|
2019
Q3 | $564K | Buy |
4,177
+161
| +4% | +$21.1K | ﹤0.01% | 365 |
|
|
2019
Q2 | $490K | Sell |
4,016
-412
| -9% | -$45.6K | ﹤0.01% | 388 |
|
|
2019
Q1 | $460K | Buy |
4,428
+48
| +1% | +$4.95K | ﹤0.01% | 375 |
|
|
2018
Q4 | $499K | Buy |
+4,380
| New | +$469K | 0.01% | 348 |
|
Other funds holding RMD
VCM
VPM
DAM
Wealthfront Advisers's RMD Position: Q1 2026 in Review
Wealthfront Advisers reduced its ResMed (RMD) stake by 14% in Q1 2026, selling an estimated $419K and leaving 10,514 shares worth $2.36M. The position accounts for 0.01% of the portfolio, ranked #575.
Wealthfront Advisers first reported a position in RMD in Q4 2018 and has held it in 30 quarters since. The position peaked at $3.79M in Q3 2025. 938 funds tracked by Wall St. Rank hold RMD as of Q1 2026.
- Wealthfront Advisers held 10,514 shares of ResMed worth $2.36M as of Q1 2026.
- Wealthfront Advisers sold 1,682 ResMed shares in Q1 2026, an estimated $419K.
- ResMed made up 0.01% of Wealthfront Advisers's portfolio in Q1 2026, its #575 holding.
- Wealthfront Advisers first reported a position in ResMed in Q4 2018 and has held it in 30 quarters since.
- Wealthfront Advisers's ResMed position peaked at $3.79M in Q3 2025.
- 938 funds tracked by Wall St. Rank held ResMed as of Q1 2026.
Based on Wealthfront Advisers's 13F filing for Q1 2026, filed 5 May 2026.